<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00344253</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT-Number: 2004-004403-37</org_study_id>
    <nct_id>NCT00344253</nct_id>
  </id_info>
  <brief_title>Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis</brief_title>
  <official_title>A Monocentric, Randomized, Controlled Trial to Test the Efficacy of Interferon-beta in the Treatment of Disseminated Encephalomyelitis (ED)-Associated and Primary Intermediate Uveitis in Comparison to Standard Treatment (TEAM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Serono GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if interferon beta is superior to the standard
      treatment with Methotrexate for the treatment of intermediate uveitis and macular edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Deuter et al were the first to show the anti-edematous effect of interferon alpha on
      inflammatory macular edema (Deuter C. M. E., Kötter I., Günaydin I., Zierhut M. Treatment of
      the Cystoid Macular Oedema in Behçet's Disease with Interferon Alfa-2a, Retina, in press). In
      an interventional, multi-centric pilot-study we could demonstrate a positive effect of
      interferon beta on ED associated uveitis, especially in reducing the macular edema. Undesired
      effects of the treatment were not observed.

      Thus we want to test the efficacy and safety of interferon beta compared to standard
      treatment with methotrexate in a prospective, clinically controlled trial on patients who
      suffer from intermediate uveitis with inflammatory macular edema who either have associated
      ED or have no systemic disease association, i.e. primary uveitis. .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in visual acuity (3 lines ETDRS)at month 1,3,6 and 12</measure>
    <time_frame>at month 1,3,6 and 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of macular edema (OCT)</measure>
    <time_frame>at month 1,3,6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction intraocular inflammation (2 step change, SUN classification)</measure>
    <time_frame>at month 1,3,6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in retinal light sensitivity (fundus controlled perimetry)</measure>
    <time_frame>at month 1,3 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Uveitis, Intermediate</condition>
  <condition>Macular Edema</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interferon beta 3x weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methotrexate sc 20 mg weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon beta</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients age 18 and over

          -  Active uni- or bilateral non-infectious intermediate uveitis of at least 1 year
             duration

          -  Visual acuity on the worse eye at least 0.1 (20/200) and maximally 0.6 (20/30) caused
             by macular edema, defined by foveal thickness ≥ 250 µm

          -  Either primary uveitis or diagnosis of Multiple Sclerosis

          -  Previous treatment with oral corticosteroids in a dose of 0.5 mg per kg bodyweight of
             prednisone equivalent without sufficient success

          -  Previous treatment with other immunosuppressive drugs is facultative

        Exclusion Criteria:

          -  Exclusively anterior uveitis

          -  Absence of macular edema

          -  Optic nerve atrophy after neuritis nervi optici

          -  Peri-or intraocular injection of corticosteroids in the previous 3 months

          -  Allergies against any interferon

          -  Depression diagnosed by a psychiatrist

          -  Hepatic disease

          -  Infectious Uveitis

          -  Other auto-immune diseases but MS

          -  Pregnancy, Lactation

          -  Lack of reliable contraception

          -  Patients with metabolic, psychiatric or neoplastic diseases

          -  Active diseases like asthma, psoriasis or inflammatory bowel disease who have to be
             treated with corticosteroids

          -  primary or secondary immune deficiency

          -  Tuberculosis or other infectious lung diseases

          -  Hepatitis B or C

          -  Life vaccination during the trial duration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias D Becker, MD, PhD,FEBO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Interdisciplinary Uveitis Center, University of Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Friederike Mackensen, MD, FEBO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Interdisciplinary Uveitis Center,University of Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Regina Max, MD</last_name>
    <role>Study Director</role>
    <affiliation>Interdisciplinary Uveitis Center,University of Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Interdisciplinary Uveitis Center, University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.klinikum.uni-heidelberg.de/Home.108029.0.html</url>
    <description>Homepage with further information and downloads</description>
  </link>
  <reference>
    <citation>Becker MD, Heiligenhaus A, Hudde T, Storch-Hagenlocher B, Wildemann B, Barisani-Asenbauer T, Thimm C, Stübiger N, Trieschmann M, Fiehn C. Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol. 2005 Oct;89(10):1254-7.</citation>
    <PMID>16170111</PMID>
  </reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2006</study_first_submitted>
  <study_first_submitted_qc>June 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2006</study_first_posted>
  <last_update_submitted>November 30, 2012</last_update_submitted>
  <last_update_submitted_qc>November 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Friederike Mackensen</investigator_full_name>
    <investigator_title>PD Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Uveitis</keyword>
  <keyword>Macular Edema</keyword>
  <keyword>Interferon</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Encephalomyelitis disseminata (ED)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Encephalomyelitis</mesh_term>
    <mesh_term>Uveitis, Intermediate</mesh_term>
    <mesh_term>Pars Planitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

